27 results on '"Hilbers, Florentine S."'
Search Results
2. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
- Author
-
Delaloge, Suzette, Piccart, Martine, Rutgers, Emiel, Litière, Saskia, van 't Veer, Laura J, van den Berkmortel, Franchette, Brain, Etienne, Dudek-Peric, Aleksandra, Gil-Gil, Miguel, Gomez, Patricia, Hilbers, Florentine S, Khalil, Zaman, Knox, Susan, Kuemmel, Sherko, Kunz, Georg, Lesur, Anne, Pierga, Jean-Yves, Ravdin, Peter, Rubio, Isabel T, Saghatchian, Mahasti, Smilde, Tineke J, Thompson, Alastair M, Viale, Giuseppe, Zoppoli, Gabriele, Vuylsteke, Peter, Tryfonidis, Konstantinos, Poncet, Coralie, Bogaerts, Jan, and Cardoso, Fatima
- Subjects
Genetics ,Rare Diseases ,Breast Cancer ,Clinical Trials and Supportive Activities ,Human Genome ,Cancer ,Clinical Research ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Adult ,Aged ,Aged ,80 and over ,Anthracyclines ,Antineoplastic Combined Chemotherapy Protocols ,Breast Neoplasms ,Capecitabine ,Docetaxel ,Female ,Humans ,Middle Aged ,Prospective Studies ,MINDACT investigators and the TRANSBIG Consortium ,Clinical Sciences ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
PurposeMINDACT demonstrated that 46% of patients with early breast cancer at high clinical but low genomic risk on the basis of MammaPrint may safely avoid adjuvant chemotherapy. A second random assignment (R-C) compared docetaxel-capecitabine with an anthracycline-based regimen.Patients and methodsR-C randomly assigned patients 1:1 between standard anthracycline-based regimens, with or without taxanes (control) and experimental docetaxel 75 mg/m2 intravenously plus oral capecitabine 825 mg/m2 two times per day for 14 days (DC) every 3 weeks for 6 cycles. The primary end point was disease-free survival (DFS). Secondary end points included overall survival and safety.ResultsOf 2,832 patients, 1,301 (45%) were randomly assigned, and 97% complied with R-C assignment. In the control arm, 29.6% only received taxanes (0.5% of N0 patients). DFS events (n = 148) were much less than required (n = 422) as a result of a lower-than-expected accrual and event rate. At 5 years of median follow-up, DFS was not different between DC (n = 652) and control (n = 649; 90.7% [95% CI, 88% to 92.8%] v 88.8% [95% CI, 85.9% to 91.1%]; hazard ratio [HR], 0.83 [95% CI, 0.60 to 1.15]; P = .26). Overall survival (HR, 0.91 [95% CI, 0.54 to 1.53]) and DFS in the clinical high and genomic high-risk subgroup (86.1% v 88.1%; HR, 0.83 [95% CI, 0.58 to 1.21]) were similar in both arms. DC led to more grade 1 neuropathy (27.1% v 11.2%) and more grade 2 hand/foot syndrome (28.5% v 3.3%) and diarrhea (13.7% v 5.8%). Serious cardiac events occurred in 9 patients (control, n = 4; DC, n = 5). Fifty-three patients developed second cancers (control, n = 32; DC, n = 21; leukemia: 2 v 1). Five treatment-related deaths occurred (control, 2 [0.3%]; DC, 3 [0.5%]).ConclusionAlthough underpowered, this second randomization in MINDACT did not show any improvement in outcome or safety with the use of DC compared with anthracycline-based chemotherapy.
- Published
- 2020
3. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
- Author
-
Lambertini, Matteo, Agbor-Tarh, Dominique, Metzger-Filho, Otto, Ponde, Noam F., Poggio, Francesca, Hilbers, Florentine S., Korde, Larissa A., Chumsri, Saranya, Werner, Olena, Del Mastro, Lucia, Caparica, Rafael, Moebus, Volker, Moreno-Aspitia, Alvaro, Piccart, Martine J., and de Azambuja, Evandro
- Published
- 2020
- Full Text
- View/download PDF
4. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
- Author
-
Eiger, Daniel, Pondé, Noam F., Agbor-Tarh, Dominique, Moreno-Aspitia, Alvaro, Piccart, Martine, Hilbers, Florentine S., Werner, Olena, Chumsri, Saranya, Dueck, Amylou, Kroep, Judith R., Gomez, Henry, Láng, István, Rodeheffer, Richard J., Ewer, Michael S., Suter, Thomas, and de Azambuja, Evandro
- Published
- 2020
- Full Text
- View/download PDF
5. Supplementary file - liver genes from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
- Author
-
Aftimos, Philippe, primary, Oliveira, Mafalda, primary, Irrthum, Alexandre, primary, Fumagalli, Debora, primary, Sotiriou, Christos, primary, Gal-Yam, Einav Nili, primary, Robson, Mark E., primary, Ndozeng, Justin, primary, Di Leo, Angelo, primary, Ciruelos, Eva M., primary, de Azambuja, Evandro, primary, Viale, Giuseppe, primary, Scheepers, Elsemieke D., primary, Curigliano, Giuseppe, primary, Bliss, Judith M., primary, Reis-Filho, Jorge S., primary, Colleoni, Marco, primary, Balic, Marija, primary, Cardoso, Fatima, primary, Albanell, Joan, primary, Duhem, Caroline, primary, Marreaud, Sandrine, primary, Romagnoli, Dario, primary, Rojas, Beatriz, primary, Gombos, Andrea, primary, Wildiers, Hans, primary, Guerrero-Zotano, Angel, primary, Hall, Peter, primary, Bonetti, Andrea, primary, Larsson, Karolina Fs, primary, Degiorgis, Martina, primary, Khodaverdi, Silvia, primary, Greil, Richard, primary, Sverrisdóttir, Ásgerdur, primary, Paoli, Marta, primary, Seyll, Ethel, primary, Loibl, Sibylle, primary, Linderholm, Barbro, primary, Zoppoli, Gabriele, primary, Davidson, Nancy E., primary, Johannsson, Oskar Th, primary, Bedard, Philippe L., primary, Loi, Sherene, primary, Knox, Susan, primary, Cameron, David A., primary, Harbeck, Nadia, primary, Montoya, Maite Lasa, primary, Brandão, Mariana, primary, Vingiani, Andrea, primary, Caballero, Carmela, primary, Hilbers, Florentine S., primary, Yates, Lucy R., primary, Benelli, Matteo, primary, Venet, David, primary, and Piccart, Martine J., primary
- Published
- 2023
- Full Text
- View/download PDF
6. Data from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
- Author
-
Aftimos, Philippe, primary, Oliveira, Mafalda, primary, Irrthum, Alexandre, primary, Fumagalli, Debora, primary, Sotiriou, Christos, primary, Gal-Yam, Einav Nili, primary, Robson, Mark E., primary, Ndozeng, Justin, primary, Di Leo, Angelo, primary, Ciruelos, Eva M., primary, de Azambuja, Evandro, primary, Viale, Giuseppe, primary, Scheepers, Elsemieke D., primary, Curigliano, Giuseppe, primary, Bliss, Judith M., primary, Reis-Filho, Jorge S., primary, Colleoni, Marco, primary, Balic, Marija, primary, Cardoso, Fatima, primary, Albanell, Joan, primary, Duhem, Caroline, primary, Marreaud, Sandrine, primary, Romagnoli, Dario, primary, Rojas, Beatriz, primary, Gombos, Andrea, primary, Wildiers, Hans, primary, Guerrero-Zotano, Angel, primary, Hall, Peter, primary, Bonetti, Andrea, primary, Larsson, Karolina Fs, primary, Degiorgis, Martina, primary, Khodaverdi, Silvia, primary, Greil, Richard, primary, Sverrisdóttir, Ásgerdur, primary, Paoli, Marta, primary, Seyll, Ethel, primary, Loibl, Sibylle, primary, Linderholm, Barbro, primary, Zoppoli, Gabriele, primary, Davidson, Nancy E., primary, Johannsson, Oskar Th, primary, Bedard, Philippe L., primary, Loi, Sherene, primary, Knox, Susan, primary, Cameron, David A., primary, Harbeck, Nadia, primary, Montoya, Maite Lasa, primary, Brandão, Mariana, primary, Vingiani, Andrea, primary, Caballero, Carmela, primary, Hilbers, Florentine S., primary, Yates, Lucy R., primary, Benelli, Matteo, primary, Venet, David, primary, and Piccart, Martine J., primary
- Published
- 2023
- Full Text
- View/download PDF
7. Supplementary methods, tables and figures. from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
- Author
-
Aftimos, Philippe, primary, Oliveira, Mafalda, primary, Irrthum, Alexandre, primary, Fumagalli, Debora, primary, Sotiriou, Christos, primary, Gal-Yam, Einav Nili, primary, Robson, Mark E., primary, Ndozeng, Justin, primary, Di Leo, Angelo, primary, Ciruelos, Eva M., primary, de Azambuja, Evandro, primary, Viale, Giuseppe, primary, Scheepers, Elsemieke D., primary, Curigliano, Giuseppe, primary, Bliss, Judith M., primary, Reis-Filho, Jorge S., primary, Colleoni, Marco, primary, Balic, Marija, primary, Cardoso, Fatima, primary, Albanell, Joan, primary, Duhem, Caroline, primary, Marreaud, Sandrine, primary, Romagnoli, Dario, primary, Rojas, Beatriz, primary, Gombos, Andrea, primary, Wildiers, Hans, primary, Guerrero-Zotano, Angel, primary, Hall, Peter, primary, Bonetti, Andrea, primary, Larsson, Karolina Fs, primary, Degiorgis, Martina, primary, Khodaverdi, Silvia, primary, Greil, Richard, primary, Sverrisdóttir, Ásgerdur, primary, Paoli, Marta, primary, Seyll, Ethel, primary, Loibl, Sibylle, primary, Linderholm, Barbro, primary, Zoppoli, Gabriele, primary, Davidson, Nancy E., primary, Johannsson, Oskar Th, primary, Bedard, Philippe L., primary, Loi, Sherene, primary, Knox, Susan, primary, Cameron, David A., primary, Harbeck, Nadia, primary, Montoya, Maite Lasa, primary, Brandão, Mariana, primary, Vingiani, Andrea, primary, Caballero, Carmela, primary, Hilbers, Florentine S., primary, Yates, Lucy R., primary, Benelli, Matteo, primary, Venet, David, primary, and Piccart, Martine J., primary
- Published
- 2023
- Full Text
- View/download PDF
8. Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer
- Author
-
Vliek, Sonja B., primary, Hilbers, Florentine S., additional, Jager, Agnes, additional, Retèl, Valesca P., additional, Bueno de Mesquita, Jolien M., additional, Drukker, Caroline A., additional, Veltkamp, Sanne C., additional, Zeillemaker, Anneke M., additional, Rutgers, Emiel J., additional, van Tinteren, Harm, additional, van Harten, Wim H., additional, van 't Veer, Laura J., additional, van de Vijver, Marc J., additional, and Linn, Sabine C., additional
- Published
- 2022
- Full Text
- View/download PDF
9. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
- Author
-
Malorni, Luca, Tyekucheva, Svitlana, Hilbers, Florentine S, Ignatiadis, Michail, Neven, Patrick, Colleoni, Marco, HENRY, Stéphanie, Ballestrero, Alberto, Bonetti, Andrea, Jerusalem, Guy, Papadimitriou, Konstantinos, Bernardo, Antonio, Seles, Elena, Duhoux, Francois, MacPherson, Iain R, Thomson, Alastair, Davies, David Mark, Bergqvist, Mattias, Migliaccio, Ilenia, Gebhart, Géraldine, Zoppoli, Gabriele, Bliss, Judith M, Benelli, Matteo, McCartney, Amelia, Kammler, Roswitha, De Swert, Heidi, Ruepp, Barbara, Fumagalli, Debora, Maibach, Rudolf, Cameron, David, Loi, Sherene, Piccart, Martine, Regan, Meredith M, International Breast Cancer Study Group, Breast International Group and PYTHIA Collaborators, UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, International Breast Cancer Study Group, Breast International Group, and PYTHIA Collaborators
- Subjects
Male ,Cancer Research ,Pyridines ,Cyclin-Dependent Kinase 4 ,Breast Neoplasms ,Palbociclib ,Prognostic factors ,Piperazines ,Serum markers ,Breast cancer ,Thymidine kinase ,Oncology ,Fulvestrant ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Prospective Studies ,Human medicine - Abstract
Background:\ud \ud Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation marker downstream of the cyclin-dependent kinase 4/6 pathway. We prospectively investigated the prognostic role of serum thymidine kinase activity (sTKa), in patients treated with Palbociclib + fulvestrant.\ud \ud Patients and methods:\ud \ud PYTHIA was a phase II, single-arm, multicentre, trial that enrolled 124 post-menopausal women with endocrine-resistant hormone receptor-positive/HER2-negative metastatic breast cancer. Serum samples were collected pre-treatment (pre-trt; n = 122), at day 15 of cycle 1 (D15; n = 108), during the one week-off palbociclib before initiating cycle 2 (D28; n = 108) and at end of treatment (n = 76). sTKa was determined centrally using Divitum®, a refined ELISA-based assay with a limit of detection of 20 Divitum Units (Du)/L. The primary study endpoint was progression-free survival, assessed for its association with pre- and on-treatment sTKa.\ud \ud Results:\ud \ud Data from 122 women were analysed. Pre-treatment sTKa was not associated with clinical characteristics and moderately correlated with tissue Ki-67. Palbociclib + fulvestrant markedly suppressed sTKa levels at D15, with 83% of patients recording levels below limit of detection. At D28, sTKa showed a rebound in 60% of patients. At each timepoint, higher sTKa was associated with shorter progression-free survival (each p < 0.001), with the strongest effect at D15.\ud \ud Conclusions:\ud \ud STKa is an independent prognostic biomarker in patients treated with palbociclib. High pre-treatment sTKa and its incomplete suppression during treatment may identify patients with poorer prognosis and primary resistance. This warrants validation in prospective comparative trials.\ud \ud Clinicaltrials.gov identifier:\ud \ud NCT02536742; EudraCT 2014-005387-15.
- Published
- 2022
10. FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor
- Author
-
Peterlongo, Paolo, Catucci, Irene, Colombo, Mara, Caleca, Laura, Mucaki, Eliseos, Bogliolo, Massimo, Marin, Maria, Damiola, Francesca, Bernard, Loris, Pensotti, Valeria, Volorio, Sara, DallʼOlio, Valentina, Meindl, Alfons, Bartram, Claus, Sutter, Christian, Surowy, Harald, Sornin, Valérie, Dondon, Marie-Gabrielle, Eon-Marchais, Séverine, Stoppa-Lyonnet, Dominique, Andrieu, Nadine, Sinilnikova, Olga M., Mitchell, Gillian, James, Paul A., Thompson, Ella, Marchetti, Marina, Verzeroli, Cristina, Tartari, Carmen, Capone, Gabriele Lorenzo, Putignano, Anna Laura, Genuardi, Maurizio, Medici, Veronica, Marchi, Isabella, Federico, Massimo, Tognazzo, Silvia, Matricardi, Laura, Agata, Simona, Dolcetti, Riccardo, Puppa, Lara Della, Cini, Giulia, Gismondi, Viviana, Viassolo, Valeria, Perfumo, Chiara, Mencarelli, Maria Antonietta, Baldassarri, Margherita, Peissel, Bernard, Roversi, Gaia, Silvestri, Valentina, Rizzolo, Piera, Spina, Francesca, Vivanet, Caterina, Tibiletti, Maria Grazia, Caligo, Maria Adelaide, Gambino, Gaetana, Tommasi, Stefania, Pilato, Brunella, Tondini, Carlo, Corna, Chiara, Bonanni, Bernardo, Barile, Monica, Osorio, Ana, Benitez, Javier, Balestrino, Luisa, Ottini, Laura, Manoukian, Siranoush, Pierotti, Marco A., Renieri, Alessandra, Varesco, Liliana, Couch, Fergus J., Wang, Xianshu, Devilee, Peter, Hilbers, Florentine S., van Asperen, Christi J., Viel, Alessandra, Montagna, Marco, Cortesi, Laura, Diez, Orland, Balmaña, Judith, Hauke, Jan, Schmutzler, Rita K., Papi, Laura, Pujana, Miguel Angel, Lázaro, Conxi, Falanga, Anna, Offit, Kenneth, Vijai, Joseph, Campbell, Ian, Burwinkel, Barbara, Kvist, Anders, Ehrencrona, Hans, Mazoyer, Sylvie, Pizzamiglio, Sara, Verderio, Paolo, Surralles, Jordi, Rogan, Peter K., and Radice, Paolo
- Published
- 2015
- Full Text
- View/download PDF
11. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
- Author
-
Aftimos, Philippe, primary, Oliveira, Mafalda, additional, Irrthum, Alexandre, additional, Fumagalli, Debora, additional, Sotiriou, Christos, additional, Gal-Yam, Einav Nili, additional, Robson, Mark E., additional, Ndozeng, Justin, additional, Di Leo, Angelo, additional, Ciruelos, Eva M., additional, de Azambuja, Evandro, additional, Viale, Giuseppe, additional, Scheepers, Elsemieke D., additional, Curigliano, Giuseppe, additional, Bliss, Judith M., additional, Reis-Filho, Jorge S., additional, Colleoni, Marco, additional, Balic, Marija, additional, Cardoso, Fatima, additional, Albanell, Joan, additional, Duhem, Caroline, additional, Marreaud, Sandrine, additional, Romagnoli, Dario, additional, Rojas, Beatriz, additional, Gombos, Andrea, additional, Wildiers, Hans, additional, Guerrero-Zotano, Angel, additional, Hall, Peter, additional, Bonetti, Andrea, additional, Larsson, Karolina Fs, additional, Degiorgis, Martina, additional, Khodaverdi, Silvia, additional, Greil, Richard, additional, Sverrisdóttir, Ásgerdur, additional, Paoli, Marta, additional, Seyll, Ethel, additional, Loibl, Sibylle, additional, Linderholm, Barbro, additional, Zoppoli, Gabriele, additional, Davidson, Nancy E., additional, Johannsson, Oskar Th, additional, Bedard, Philippe L., additional, Loi, Sherene, additional, Knox, Susan, additional, Cameron, David A., additional, Harbeck, Nadia, additional, Montoya, Maite Lasa, additional, Brandão, Mariana, additional, Vingiani, Andrea, additional, Caballero, Carmela, additional, Hilbers, Florentine S., additional, Yates, Lucy R., additional, Benelli, Matteo, additional, Venet, David, additional, and Piccart, Martine J., additional
- Published
- 2021
- Full Text
- View/download PDF
12. Abstract PS5-05: Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial
- Author
-
Malorni, Luca, primary, Tyekucheva, Svitlana, additional, Hilbers, Florentine S, additional, Ignatiadis, Michail, additional, Neven, Patrick, additional, Colleoni, Marco, additional, Henry, Stéphanie, additional, Ballestrero, Alberto, additional, Bonetti, Andrea, additional, Jerusalem, Guy, additional, Papadimitriou, Konstantinos, additional, Bernardo, Antonio, additional, Duhoux, Francois, additional, MacPherson, Iain, additional, Thomson, Alastair, additional, Davies, David Mark, additional, Bergqvist, Mattias, additional, Benelli, Matteo, additional, McCartney, Amelia, additional, De Swert, Heidi, additional, Ruepp, Barbara, additional, Rabaglio, Manuela, additional, Maibach, Rudolf, additional, Piccart, Martine, additional, and Regan, Meredith M, additional
- Published
- 2021
- Full Text
- View/download PDF
13. Rare variants in XRCC2 as breast cancer susceptibility alleles
- Author
-
Hilbers, Florentine S, Wijnen, Juul T, Hoogerbrugge, Nicoline, Oosterwijk, Jan C, Collee, Margriet J, Peterlongo, Paolo, Radice, Paolo, Manoukian, Siranoush, Feroce, Irene, Capra, Fabio, Couch, Fergus J, Wang, Xianshu, Guidugli, Lucia, Offit, Kenneth, Shah, Sohela, Campbell, Ian G, Thompson, Ella R, James, Paul A, Trainer, Alison H, Gracia, Javier, Benitez, Javier, van Asperen, Christi J, and Devilee, Peter
- Published
- 2012
- Full Text
- View/download PDF
14. Abstract 2488: Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program
- Author
-
Benelli, Matteo, primary, Biagioni, Chiara, additional, Fimereli, Danai, additional, Hilbers, Florentine S., additional, De Angelis, Claudia, additional, Vivancos, Ana, additional, Venet, David, additional, Vingiani, Andrea, additional, Irrthum, Alexandre, additional, Van Dooren, Veerle, additional, Vuylsteke, Peter Willem, additional, Servitja, Sonia, additional, Reis-Filho, Jorge, additional, Curigliano, Giuseppe, additional, Oliveira, Mafalda, additional, Piccart, Martine, additional, and Aftimos, Philippe, additional
- Published
- 2020
- Full Text
- View/download PDF
15. Clustering of known low and moderate risk alleles rather than a novel recessive high‐risk gene in non‐ BRCA1 /2 sib trios affected with breast cancer
- Author
-
Hilbers, Florentine S., primary, Hof, Peter J., additional, Meijers, Caro M., additional, Mei, Hailiang, additional, Michailidou, Kyriaki, additional, Dennis, Joe, additional, Hogervorst, Frans B. L., additional, Nederlof, Petra M., additional, Asperen, Christi J., additional, and Devilee, Peter, additional
- Published
- 2020
- Full Text
- View/download PDF
16. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
- Author
-
Di Cosimo, Serena, primary, Appierto, Valentina, additional, Pizzamiglio, Sara, additional, Silvestri, Marco, additional, Baselga, José, additional, Piccart, Martine, additional, Huober, Jens, additional, Izquierdo, Miguel, additional, de la Pena, Lorena, additional, Hilbers, Florentine S., additional, de Azambuja, Evandro, additional, Untch, Michael, additional, Pusztai, Lajos, additional, Pritchard, Kathleen, additional, Nuciforo, Paolo, additional, Vincent-Salomon, Anne, additional, Symmans, Fraser, additional, Apolone, Giovanni, additional, de Braud, Filippo G., additional, Iorio, Marilena V., additional, Verderio, Paolo, additional, and Daidone, Maria Grazia, additional
- Published
- 2020
- Full Text
- View/download PDF
17. Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2breast cancer families
- Author
-
Lakeman, Inge M M, primary, Hilbers, Florentine S, additional, Rodríguez-Girondo, Mar, additional, Lee, Andrew, additional, Vreeswijk, Maaike P G, additional, Hollestelle, Antoinette, additional, Seynaeve, Caroline, additional, Meijers-Heijboer, Hanne, additional, Oosterwijk, Jan C, additional, Hoogerbrugge, Nicoline, additional, Olah, Edith, additional, Vasen, Hans F A, additional, van Asperen, Christi J, additional, and Devilee, Peter, additional
- Published
- 2019
- Full Text
- View/download PDF
18. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials
- Author
-
Lambertini, Matteo, primary, Martel, Samuel, additional, Campbell, Christine, additional, Guillaume, Sébastien, additional, Hilbers, Florentine S., additional, Schuehly, Uwe, additional, Korde, Larissa, additional, Azim, Hatem A., additional, Di Cosimo, Serena, additional, Tenglin, Richard C., additional, Huober, Jens, additional, Baselga, José, additional, Moreno‐Aspitia, Alvaro, additional, Piccart‐Gebhart, Martine, additional, Gelber, Richard D., additional, de Azambuja, Evandro, additional, and Ignatiadis, Michail, additional
- Published
- 2018
- Full Text
- View/download PDF
19. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.
- Author
-
Piccart, Martine J., Hilbers, Florentine S., Bliss, Judith M., Caballero, Carmela, Frank, Elizabeth S., Renault, Patrick, Naït Kaoudjt, Rachida, Schumacher, Eva, Spears, Patricia A., Regan, Meredith M., Gelber, Richard D., Davidson, Nancy E., Norton, Larry, Winer, Eric P., and BIG-NABCG Collaboration
- Published
- 2020
- Full Text
- View/download PDF
20. Clustering of known low and moderate risk alleles rather than a novel recessive high‐risk gene in non‐BRCA1/2 sib trios affected with breast cancer.
- Author
-
Hilbers, Florentine S., Hof, Peter J., Meijers, Caro M., Mei, Hailiang, Michailidou, Kyriaki, Dennis, Joe, Hogervorst, Frans B. L., Nederlof, Petra M., Asperen, Christi J., and Devilee, Peter
- Subjects
RECESSIVE genes ,BREAST cancer ,ALLELES ,FAMILY history (Medicine) ,CANCER susceptibility - Abstract
Breast cancer risk is approximately twice as high in first‐degree relatives of female breast cancer cases than in women in the general population. Less than half of this risk can be attributed to the currently known genetic risk factors. Recessive risk alleles represent a relatively underexplored explanation for the remainder of familial risk. To address this, we selected 19 non‐BRCA1/2 breast cancer families in which at least three siblings were affected, while no first‐degree relatives of the previous or following generation had breast cancer. Germline DNA from one of the siblings was subjected to exome sequencing, while all affected siblings were genotyped using SNP arrays to assess haplotype sharing and to calculate a polygenic risk score (PRS) based on 160 low‐risk variants. We found no convincing candidate recessive alleles among exome sequencing variants in genomic regions for which all three siblings shared two haplotypes. However, we found two families in which all affected siblings carried the CHEK2*1100delC. In addition, the average normalized PRS of the "recessive" family probands (0.81) was significantly higher than that in both general population cases (0.35, P =.026) and controls (P =.0004). These findings suggest that the familial aggregation is, at least in part, explained by a polygenic effect of common low‐risk variants and rarer intermediate‐risk variants, while we did not find evidence of a role for novel recessive risk alleles. What's new? To find new breast cancer susceptibility alleles, these authors tested families in which at least three affected siblings had non‐BRCA1/2 breast cancer. No new susceptibility alleles emerged, but the analysis did reveal that on average, women from these families who had cancer had significantly higher polygenic risk scores than either sporadic cases or controls. This result highlights the importance of moderate risk alleles acting together in familial breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non-BRCA1/2 breast cancer families.
- Author
-
Lakeman, Inge M. M., Hilbers, Florentine S., Rodríguez-Girondo, Mar, Lee, Andrew, Vreeswijk, Maaike P. G., Hollestelle, Antoinette, Seynaeve, Caroline, Meijers-Heijboer, Hanne, Oosterwijk, Jan C., Hoogerbrugge, Nicoline, Olah, Edith, Vasen, Hans F. A., van Asperen, Christi J., and Devilee, Peter
- Abstract
Background The currently known breast cancerassociated single nucleotide polymorphisms (SNPs) are presently not used to guide clinical management. We explored whether a genetic test that incorporates a SNPbased polygenic risk score (PRS) is clinically meaningful in non-BRCA1/2 high-risk breast cancer families. Methods 101 non-BRCA1/2 high-risk breast cancer families were included; 323 cases and 262 unaffected female relatives were genotyped. The 161-SNP PRS was calculated and standardised to 327 population controls (sPRS). Association analysis was performed using a Cox-type random effect regression model adjusted by family history. Updated individualised breast cancer lifetime risk scores were derived by combining the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm breast cancer lifetime risk with the effect of the sPRS. Results The mean sPRS for cases and their unaffected relatives was 0.70 (SD=0.9) and 0.53 (SD=0.9), respectively. A significant association was found between sPRS and breast cancer, HR=1.16, 95% CI 1.03 to 1.28, p=0.026. Addition of the sPRS to risk prediction based on family history alone changed screening recommendations in 11.5%, 14.7% and 19.8% of the women according to breast screening guidelines from the USA (National Comprehensive Cancer Network), UK (National Institute for Health and Care Excellence and the Netherlands (Netherlands Comprehensive Cancer Organisation), respectively. Conclusion Our results support the application of the PRS in risk prediction and clinical management of women from genetically unexplained breast cancer families. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
- Author
-
Lambertini, Matteo, Martel, Samuel, Campbell, Christine, Guillaume, Sébastien, Hilbers, Florentine S., Schuehly, Uwe, Korde, Larissa, Azim, Hatem A., Di Cosimo, Serena, Tenglin, Richard C., Huober, Jens, Baselga, José, Moreno‐Aspitia, Alvaro, Piccart‐Gebhart, Martine, Gelber, Richard D., de Azambuja, Evandro, Ignatiadis, Michail, Azim, Hatem A , Jr, Moreno-Aspitia, Alvaro, and Piccart-Gebhart, Martine
- Subjects
EPIDERMAL growth factor ,PREGNANCY ,PROGNOSIS ,BREAST cancer ,TRASTUZUMAB ,PATIENTS ,THERAPEUTIC use of antineoplastic agents ,BREAST tumors ,CELL receptors ,COMBINED modality therapy ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,PREGNANCY complications ,RESEARCH ,EVALUATION research ,RANDOMIZED controlled trials ,PREGNANCY outcomes - Abstract
Background: Limited data exist on the safety of using anti-human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients with a pregnancy after prior early breast cancer, with no data in HER2-positive patients.Methods: The Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial and the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial were randomized phase 3 trials for patients with HER2-positive early breast cancer. In both trials, pregnancy information was prospectively collected. Pregnancy outcomes were compared between patients unintentionally exposed to trastuzumab and/or lapatinib during gestation (the exposed group) and those who became pregnant after trastuzumab and/or lapatinib completion (the unexposed group). In the ALTTO trial, disease-free survival (DFS) was compared between pregnant patients and those aged 40 years or younger without a subsequent pregnancy via an extended Cox model with time-varying covariates to account for a guarantee-time bias.Results: Ninety-two patients (12 in the exposed group and 80 in the unexposed group) had a pregnancy: 7 in the NeoALTTO trial and 85 in the ALTTO trial. Seven patients (58.3%) in the exposed group and 10 patients (12.5%) in the unexposed group opted for an induced abortion; in the unexposed group, 10 patients (12.5%) had a spontaneous abortion. No pregnancy/delivery complications were reported for the remaining cases, who successfully completed their pregnancy, with the exception of 1 fetus with trisomy 21 (Down syndrome). No significant difference in DFS (adjusted hazard ratio, 1.12; 95% confidence interval, 0.52-2.42) was observed between young patients with a pregnancy (n = 85) and young patients without a pregnancy (n = 1307).Conclusions: For patients with HER2-positive early breast cancer, having a pregnancy after treatment completion appears to be safe without compromising fetal outcome or maternal prognosis. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
23. Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility GeneXRCC2
- Author
-
Hilbers, Florentine S., primary, Luijsterburg, Martijn S., additional, Wiegant, Wouter W., additional, Meijers, Caro M., additional, Völker-Albert, Moritz, additional, Boonen, Rick A., additional, van Asperen, Christi J., additional, Devilee, Peter, additional, and van Attikum, Haico, additional
- Published
- 2016
- Full Text
- View/download PDF
24. Whole Exome Sequencing Suggests Much of Non-BRCA1/BRCA2 Familial Breast Cancer Is Due to Moderate and Low Penetrance Susceptibility Alleles
- Author
-
Gracia-Aznarez, Francisco Javier, primary, Fernandez, Victoria, additional, Pita, Guillermo, additional, Peterlongo, Paolo, additional, Dominguez, Orlando, additional, de la Hoya, Miguel, additional, Duran, Mercedes, additional, Osorio, Ana, additional, Moreno, Leticia, additional, Gonzalez-Neira, Anna, additional, Rosa-Rosa, Juan Manuel, additional, Sinilnikova, Olga, additional, Mazoyer, Sylvie, additional, Hopper, John, additional, Lazaro, Conchi, additional, Southey, Melissa, additional, Odefrey, Fabrice, additional, Manoukian, Siranoush, additional, Catucci, Irene, additional, Caldes, Trinidad, additional, Lynch, Henry T., additional, Hilbers, Florentine S. M., additional, van Asperen, Christi J., additional, Vasen, Hans F. A., additional, Goldgar, David, additional, Radice, Paolo, additional, Devilee, Peter, additional, and Benitez, Javier, additional
- Published
- 2013
- Full Text
- View/download PDF
25. Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling
- Author
-
Hilbers, Florentine S., primary, Meijers, Caro M., additional, Laros, Jeroen F. J., additional, van Galen, Michiel, additional, Hoogerbrugge, Nicoline, additional, Vasen, Hans F. A., additional, Nederlof, Petra M., additional, Wijnen, Juul T., additional, van Asperen, Christi J., additional, and Devilee, Peter, additional
- Published
- 2013
- Full Text
- View/download PDF
26. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
- Author
-
Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, and Regan MM
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclin-Dependent Kinase 4, Female, Fulvestrant therapeutic use, Humans, Piperazines, Prospective Studies, Pyridines, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Thymidine Kinase therapeutic use
- Abstract
Background: Biomarkers for cyclin-dependent kinase 4/6 inhibitors, such as palbociclib, for patients with hormone receptor-positive/HER2-negative metastatic breast cancer are lacking. Thymidine kinase is a proliferation marker downstream of the cyclin-dependent kinase 4/6 pathway. We prospectively investigated the prognostic role of serum thymidine kinase activity (sTKa), in patients treated with Palbociclib + fulvestrant., Patients and Methods: PYTHIA was a phase II, single-arm, multicentre, trial that enrolled 124 post-menopausal women with endocrine-resistant hormone receptor-positive/HER2-negative metastatic breast cancer. Serum samples were collected pre-treatment (pre-trt; n = 122), at day 15 of cycle 1 (D15; n = 108), during the one week-off palbociclib before initiating cycle 2 (D28; n = 108) and at end of treatment (n = 76). sTKa was determined centrally using Divitum®, a refined ELISA-based assay with a limit of detection of 20 Divitum Units (Du)/L. The primary study endpoint was progression-free survival, assessed for its association with pre- and on-treatment sTKa., Results: Data from 122 women were analysed. Pre-treatment sTKa was not associated with clinical characteristics and moderately correlated with tissue Ki-67. Palbociclib + fulvestrant markedly suppressed sTKa levels at D15, with 83% of patients recording levels below limit of detection. At D28, sTKa showed a rebound in 60% of patients. At each timepoint, higher sTKa was associated with shorter progression-free survival (each p < 0.001), with the strongest effect at D15., Conclusions: STKa is an independent prognostic biomarker in patients treated with palbociclib. High pre-treatment sTKa and its incomplete suppression during treatment may identify patients with poorer prognosis and primary resistance. This warrants validation in prospective comparative trials. CLINICALTRIALS., Gov Identifier: NCT02536742; EudraCT 2014-005387-15., Competing Interests: Conflict of interest statement L. Malorni reports receiving research grants (institution) from Novartis and Pfizer and serving an advisory board (honoraria) for Novartis, Seagen, Pfizer. F. Hilbers reports receiving funding (to previous Institution affiliated with) from Pfizer for conduct of the PYTHIA trial. M. Ignatiadis reports receiving research grants (to Institution) from Roche, Natera Inc, and Pfizer and serving an advisory board role (honoraria) for Novartis and Seattle Genetics. M. Colleoni reports receiving a research grant (to Institution) from Roche. G. Jerusalem reports grants (to Institution), personal fees and non-financial support from Novartis, grants, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Lilly, personal fees and non-financial support from Amgen, personal fees and non-financial support from BMS, personal fees and non-financial support from Astra-Zeneca, personal fees from Daiichi Sankyo, personal fees from Abbvie, non-financial support from Medimmune, and non-financial support from Merck KGaA. K. Papadimitriou reports serving an advisory board role (honoraria) for Roche, Pfizer, Lilly, and Novartis. F.P. Duhoux reports serving an advisory role (support to Institution) for Roche, Pfizer, AstraZeneca, Lilly, Novartis, Amgen, Daiichi Sankyo, Pierre Fabre, Mundipharma, Seagen, and Teva. I. R. MacPherson reports serving as a consultant for Roche, Novartis, Pfizer, Eli Lilly, Pierre Fabre, Daiichi Sankyo, and Astrazeneca, and reports receiving travel/conference registration support from Roche, Eli Lilly, and Daichi Sankyo. A. Thomson reports receiving speaker fees from Novartis, Roche, Exact Sciences, and Lilly, reports serving on the advisory board for Novartis and MSD, and reports receiving support for attending conferences from BMS, Astellas, MSD, Ipsen, and EUSA. M. Bergqvist reports being an employee and holding stock in Biovica. G. Zoppoli reports receiving travel grants from Novartis and Roche, and reagents from ThermoFisher Scientific and Cytiva. J.M. Bliss reports receiving research funding from AstraZeneca, Merck Sharp & Dohme, Puma Biotechnology, Clovis Oncology, Pfizer, Janssen-Cilag, Novartis, Roche, and Eli Lilly. H. De Swert reports receiving research funding (to Institution) from Pfizer, Novartis, Roche, Servier, AstraZeneca, TESARO, and GSK. D. Fumagalli reports receiving research funding for the conduct of clinical trials (to Institution) from Pfizer, Biovica, Novartis, Roche/Genentech, Sanofi, Servier, AstraZeneca, TESARO, and GSK. D. Cameron reports serving on the advisory board for AstraZeneca, Pfizer, Lilly (to Institution), and IDMC (independent data monitoring committee) work (to Institution) for Lilly and unrelated research funding from Novartis. M. Piccart reports grants (to Institution) from AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, and Synthon, reports receiving honoraria from AstraZeneca, Camel-IDS, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Pfizer (funded the study conception & design component), Roche-Genentech, Seattle Genetics, Immutep, Seagen, and NBE Therapeutics, and reports serving on the Scientific Board of Oncolytics. M.M. Regan reports research funding (to Institution) from Novartis, Pfizer, Ipsen, TerSera, Pierre Fabre, Roche, AstraZeneca, Bristol-Myers Squibb, and Bayer, and reports serving a consulting/advisory role for Ipsen (support to Institution), Bristol-Myers Squibb, and Tolmar Pharmaceuticals. No disclosures were reported by the other authors., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
27. Genetic variants in TGFβ-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer.
- Author
-
Hilbers FS, Boekel NB, van den Broek AJ, van Hien R, Cornelissen S, Aleman BM, van 't Veer LJ, van Leeuwen FE, and Schmidt MK
- Subjects
- Aged, Female, Follow-Up Studies, Genetic Variation, Genotype, Humans, Middle Aged, Proportional Hazards Models, Real-Time Polymerase Chain Reaction, Retrospective Studies, Risk Factors, Survival Rate, Breast Neoplasms genetics, Breast Neoplasms radiotherapy, Cardiovascular Diseases etiology, Cardiovascular Diseases genetics, Cardiovascular System radiation effects, Plasminogen Activator Inhibitor 1 genetics, Polymorphism, Genetic, Transforming Growth Factor beta1 genetics
- Abstract
Background and Purpose: It has been established that radiotherapy can increase cardiovascular disease (CVD) risk. Genetic variants, which play a role in the tissue, damage response and angiogenesis regulating TGFβ pathway might give us insight into the mechanisms underlying radiation-induced CVD. We examined the effects of two polymorphisms, TGFβ1 29C>T and PAI-1 5G>4G, on CVD incidence., Materials and Methods: This retrospective cohort study included 422 10-year breast cancer survivors, aged <50 years at diagnosis, treated between 1977 and 1995. We collected information on treatment, oncological follow-up, CVD, CVD risk factors and genotypes., Results: During a mean follow-up of 19.4 years, 61 patients developed CVD. Internal mammary chain (IMC) irradiation, exposing a part of the heart to radiation, was associated with a hazard ratio of 2.36 (95% CI: 1.27-4.37, p=0.01) compared to no IMC irradiation. Compared to the C/C+C/T genotype, the T/T genotype of the TGFβ1 polymorphism was associated with hazard ratios of 1.79 (0.99-3.26, p=0.06) and 1.74 (0.90-3.34, p=0.10) in the total and IMC-irradiated group, respectively. We found no evidence for an association between PAI-1 5G>4G and CVD risk., Conclusion: Our study suggests there might be an association between the TGFβ1 29C>T polymorphism and CVD risk in long-term breast cancer survivors., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.